21,448 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Tri Ri Asset Management Corp

Tri Ri Asset Management Corp acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,448 shares of the biotechnology company’s stock, valued at approximately $7,686,000. United Therapeutics makes up approximately 8.6% of Tri Ri Asset Management Corp’s investment portfolio, making the stock its 2nd largest position.

A number of other large investors have also recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after acquiring an additional 33 shares during the period. Toronto Dominion Bank boosted its holdings in United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after acquiring an additional 37 shares during the period. ClariVest Asset Management LLC boosted its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. boosted its holdings in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. boosted its holdings in United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 48 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James Edgemond sold 7,802 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the transaction, the chief financial officer now owns 3,210 shares in the company, valued at approximately $1,108,766.10. The trade was a 70.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,227 shares of company stock valued at $47,398,820 in the last three months. 11.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have issued reports on UTHR. Jefferies Financial Group upped their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. TD Cowen increased their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Price Performance

UTHR stock traded up $1.13 during midday trading on Thursday, hitting $378.13. The company’s stock had a trading volume of 323,202 shares, compared to its average volume of 457,791. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The company’s fifty day moving average price is $366.18 and its 200 day moving average price is $333.84. The stock has a market capitalization of $16.88 billion, a P/E ratio of 16.61, a PEG ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.38 EPS. Equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.